745,317 Shares in Fulcrum Therapeutics, Inc. $FULC Bought by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 745,317 shares of the company’s stock, valued at approximately $2,728,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Meeder Asset Management Inc. purchased a new stake in Fulcrum Therapeutics in the 4th quarter worth $39,000. Quarry LP purchased a new position in shares of Fulcrum Therapeutics during the third quarter valued at about $35,000. Persistent Asset Partners Ltd purchased a new position in shares of Fulcrum Therapeutics during the fourth quarter valued at about $75,000. Summit Securities Group LLC bought a new stake in shares of Fulcrum Therapeutics in the first quarter worth about $53,000. Finally, Russell Investments Group Ltd. increased its holdings in shares of Fulcrum Therapeutics by 4,209.3% in the second quarter. Russell Investments Group Ltd. now owns 9,308 shares of the company’s stock worth $64,000 after purchasing an additional 9,092 shares during the last quarter. 89.83% of the stock is currently owned by institutional investors.

Fulcrum Therapeutics Stock Performance

FULC opened at $3.85 on Friday. The stock has a 50-day moving average of $3.73 and a 200 day moving average of $6.00. Fulcrum Therapeutics, Inc. has a 12 month low of $2.83 and a 12 month high of $15.74. The firm has a market cap of $293.75 million, a P/E ratio of -3.18 and a beta of 3.05.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.10). On average, research analysts forecast that Fulcrum Therapeutics, Inc. will post -0.69 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently commented on FULC. Weiss Ratings reissued a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research note on Friday, July 17th. Piper Sandler cut Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating and set a $3.00 price objective on the stock. in a report on Tuesday, June 2nd. Truist Financial cut Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $4.00 price objective on the stock. in a report on Tuesday, June 2nd. Cantor Fitzgerald downgraded Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, June 2nd. Finally, Leerink Partners lowered shares of Fulcrum Therapeutics from an “outperform” rating to a “market perform” rating and set a $4.00 target price for the company. in a report on Tuesday, June 2nd. One equities research analyst has rated the stock with a Buy rating, seven have assigned a Hold rating and four have given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Reduce” and a consensus price target of $8.20.

Insider Activity at Fulcrum Therapeutics

In other news, Director Alan Ezekowitz sold 18,000 shares of the business’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $3.65, for a total transaction of $65,700.00. Following the transaction, the director owned 10,927 shares of the company’s stock, valued at approximately $39,883.55. The trade was a 62.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 7.30% of the company’s stock.

Fulcrum Therapeutics Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.